“Global Dermatological Drugs market to grow to $39bn by 2025” says Visiongain

01 November 2019
Pharma

Visiongain has launched a new pharma report Dermatological Drugs Market Report : Psoriasis, Skin Infection, Acne, Dermatitis, Others.

The dermatological drugs market is a specialist segment of the pharmaceutical market which over the last several years has been growing at a faster rate than the overall market. This has been due partly to the high growth potential of biological treatments for psoriasis. The development of new antibacterial drugs to address the problems of population ageing and drug-resistant strains of bacteria will also contribute to the overall market growth. In other segments, high generic penetration and intense competition limit profitability.

The lead analyst of the report commented "The prevention and treatment of dermatological conditions is becoming a priority for many healthcare authorities worldwide. The increasing incidence of skin and skin structure infections (SSSI) acquired in hospitals and the community is being exacerbated by resistance to existing antibacterial therapies.

Moreover, the ageing immunocompromised population will drive the increasing prevalence of skin and skin structure infections. Throughout the forecast period, we expect global demand for dermatological drugs to increase significantly. This trend will be driven by the expansion in emerging markets, where expansion in healthcare provision will increase demand. Economic growth and the expansion of the middle class in these emerging markets will further drive the demand for dermatological treatments."

Leading companies featured in the report include AbbVie, Allergan, Amgen, Bausch Health, Bayer AG, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly, Galderma (Nestle Skin Health S.A.), GlaxoSmithKline (GSK) and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongaing.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Biopharmaceuticals Contract Manufacturing Market Report 2022-2032

Ageing population will be more susceptible to such diseases and is one of the key factors driving the growth of the global biological drugs market. In most of the developed world, the share of elderly population is almost touching a quarter of the population.

26 January 2022

Read

Visiongain Publishes Topical Drug Delivery Market Report 2022-2032

Some of the factors driving the market growth are the increasing prevalence of skin and eye diseases, high incidences of burn incidences and the growing prevalence of diabetes.

26 January 2022

Read

Visiongain Publishes Decentralized Clinical Trials Market Report 2022-2032

The growing adoption advanced e-clinical solutions, rising focus on clinical research, increasing investment in R&D, and adoption of decentralized clinical trials by biopharmaceutical companies are some of the major factors that drive the growth of the global decentralized clinical trials market.

24 January 2022

Read

Visiongain Publishes Nasal Drug Delivery Technology Market Report 2022-2032

The nasal drug delivery market will expand rapidly due to rising patient preference for nasal medication delivery due to ease of administration and efficacy, increased self-administration practises, and increased demand for home healthcare equipment.

18 January 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever